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The aim of this project was to get clearer knowledge about the spread of Borna 
disease virus (BDV) by comparing sequences from BDV infected cats from different 
regions in Sweden. BDV is associated with staggering disease (SD), a feline 
neurological disorder that causes non-suppurative meningoencephalomyelitis. 
However, cats showing signs for SD are not always confirmed to be BDV infected. In 
order to get a broader picture of the possible etiological cause/s of SD, molecular 
screening of viruses using random amplification and sequencing was performed. This 
study includes eight cats, whereas four were previously positive for BDV in nested 
RT-PCR and real-time RT-PCR analysis and four cats, only histopathology examined, 
where three showed signs for SD. Molecular epidemiology approach with RT-PCR  
and nested RT-PCR for previously positive cats gave PCR products at incorrect as 
well as correct sizes. However, sequencing showed only feline origin. Since real-time 
RT-PCR also was negative, one hypothesis is that the RNA had degraded or 
disappeared through the RNA extraction process. Nested PCR was also performed for 
the four new cats. Also here the sequencing showed only presence of feline origin. 
However, for these cats, real-time RT-PCR was positive for the pooled PCR product. 
Molecular screening of viruses for these four cats showed as before only sequences of 
feline origin. This project has identified some of the problems of studying RNA 
viruses present in small amounts in brain tissue. There is always a risk that the RNA 
is lost during the RNA extraction process. Therefore, further studies are needed to 
provide more information about the BDV molecular epidemiology in Sweden. 
Sammanfattning 
Syftet med projektet var att få mer kunskap om spridning av bornavirus (BDV) 
genom att jämföra sekvenser från BDV-infekterade katter från olika regioner i 
Sverige. BDV är associerat med vingelsjuka hos katt, en neurologisk sjukdom som 
karakteriseras av en non-purulent meningoencefalomyelit. Dock kan vingelsjuka inte 
alltid kopplas till BDV-infektion. För att få en bredare bild av tänkbara etiologiska 
orsaker till vingelsjuka utfördes även molekylär screening av virus med slumpmässig 
amplifiering och sekvensering. Här studeras åtta kattprover, varav fyra tidigare 
positiva för BDV vid PCR och realtids-PCR analyser. De resterande fyra katterna 
hade enbart undersökts histopatologiskt där tre visade tecken på vingelsjuka. PCR-
analysen för tidigare positiva katter gav band vid fel eller korrekta storlekar. 
Sekvensering visade dock enbart PCR-produkt från katt. Eftersom även resultatet från 
realtids-PCR var negativt finns det risk för att RNA har degraderat eller försvunnit 
under extraheringen. PCR-analys utfördes för de fyra nya katterna som enbart 
studerats histopatologiskt. Även här visade sekvensering enbart RNA från katt. För 
dessa katter gav emellertid realtids-PCR ett positivt resultat för poolad PCR-produkt. 
Molekylär screening av virus för dessa fyra katter visade bara på värdprodukt för både 
DNA och RNA. Detta projekt visar problematiken med RNA-virus, som finns i små 
halter i hjärnvävnad. Det finns även en risk att RNA försvinner vid extrahering av 
RNA. Därför krävs ytterligare studier för att ge mer information om molekylär 
epidemiologi av BDV i Sverige.  
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Introduction 
Viruses affect a wide variety of organisms including animals, plants, bacteria and humans. 
There are more than 4000 different viruses and 30 000 strains that could affect a living 
organism. Since viral infections in humans and animals often results in an immune response 
and disease there is a great deal of research going on within this area (Murphy et al., 1999).  
 
One viral infection that causes a neurological disease is Borna disease virus (BDV). It affects 
mainly horses and sheep in central Europe and occurs in endemic waves. Signs include 
behavioural changes and difficulty moving extremities leading to ataxia. Studies based on 
thousands of clinically diagnosed horses in Germany indicated that additional signs such as 
depression, excitation and sensory disturbances in motility could also be observed. The 
infection lasts between one to three weeks and when signs develop, the outcome is generally 
fatal. However, it has been found that animals could carry BDV without developing 
observable signs (Ludwig & Bode, 2000).  
 
BDV is associated with staggering disease (SD) also named feline Borna disease (BD), a 
feline neurological disorder showing histopathological characteristics of a viral infection in 
the central nervous system (CNS) (Lundgren, 1992; Lundgren et al., 1997). In Sweden almost 
100 diagnosed cases of SD have been reported in the last ten years. Most cases are in the 
middle of Sweden but sporadic findings of the southern and northern parts have also been 
observed (J. Wensman, unpublished data).  
 
Since BDV infected cats probably occur in endemic areas, a deeper knowledge of molecular 
epidemiology of BDV is needed and therefore phylogenetic studies of BDV could be one 
approach. However, cats showing signs for SD are not always associated and confirmed to be 
BDV affected (Staeheli et al., 2000). Therefore another approach could be to detect unknown 
viruses and/or BDV using a broader molecular screening of viruses.  However, this approach 
has some technical drawbacks and there are some problems with host ribosomal RNA when 
searching for RNA viruses. Furthermore, there are some bioinformatics problem, such as how 
to handle unknown sequences and incorrect annotations in databases (Allander et al., 2005). 
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Borna disease virus (BDV)  
History 
Clinical signs of Borna disease (BD) was probably first described in 1660, where horses with 
pain were described as dumb and dull. The name Borna has its origin from the city of Borna 
in south-eastern Germany where a severe outbreak of the disease occured around 1900. Since 
the disease had an economic impact it neccessitated extensive veterinary investigations, 
showing that the diseased horses had inflammatory reactions in the midbrain. Intranuclear 
inclusion bodies, a characteristic sign of certain viral infections were later found in the brain 
of horses and these were named Joest-Degen after the authors of this discovery. In the 1930s, 
a German veterinarian named Zwick, succeded to isolate the virus by adapting it into rabbits 
(Ludwig & Bode, 2000). However, it was not until early 1994 that the full-length genome of 
BDV was sequenced (Cubitt et al., 1994). 
 
Genome 
BD is caused by a RNA virus. Related families are Paramyxoviridae, Rhabdoviridae and 
Filoviridae, therefore BDV was classified as the family Bornaviridae in the order of 
Mononegavirales (Murphy et al., 1999). The virus genome is around 8.9 kilo bases and 
single-stranded of negative-sense and non-segmented (Cubitt & de la Torre, 1994). 
 
The spherical virions of BDV are around 90 nm in diameter and the core is around 50-60 nm 
in diameter. BDV is transcribed in the nucleus of the host cells and there the mRNA, that code 
for more than one protein (polycistronic) is produced in high levels (Murphy et al., 1999). 
Within animals, BDV is the only known negative-strand RNA virus that has this characteristic 
property (de la Torre, 2006). BDV contains six open reading frames (ORFs) that encode the 
following proteins: nucleoprotein, phosphoprotein transcriptional activator, matrix protein, 
surface glycoprotein, RNA-dependent RNA polymerase, polypeptides and the p10, see Figure 
1 (de la Torre, 2006; Kolodziejek et al., 2005). 
 
 
Figure 1. The organization of the BDV genome into six ORFs that encodes for proteins ordered in following 
direction: nucleoprotein, phosphoprotein transcriptional activator (P), matrix protein (M), surface glycoprotein 
(G), RNA-dependent RNA polymerase (L) and the p10 ORF, also named X that encodes a polypeptide of 10 
kDa (de la Torre, 2006; Kolodziejek et al., 2005).  
 
Epidemiology  
BDV infection in mammals and birds 
BDV has a broad host range including predominantly horses and sheep, but it has also been 
shown to infect cats, dogs and cattle. In horses, BDV is endemic in primarily eastern 
Germany. However, affected horses have also been found in other countries in central Europe 
including Switzerland and regions in Austria (Ludwig & Bode 2000). Antibodies to BDV 
have also been reported in sporadic findings in healthy horses in the United States of 
America, Iran and Japan (Kao et al., 1993; Bahmani et al., 1996; Hagiwara et al., 2002).  
 
In sheep, BDV is endemic in primarily Germany, and in Switzerland there have been finding 
of BDV in sheep and goat. Furthermore, BDV antibodies have also been found in Japan, 
where Hagiwara et al. (1997) found presence of antibodies in healthy sheep. Ludwig & Bode, 
(2000) have also reported prevalence of BDV antibodies in two herds of healthy sheep in 
Germany. The signs of BDV infection in sheep are the same as in horses, i.e., disturbances in 
the CNS. However, sheep show less significant signs as compared to horses. 
 
Few cases of BD in cattle have been reported in Germany and Switzerland (Bode et al., 
1994). The cattle showed neurological signs as progressive paralysis and the clinical picture 
resembles bovine spongiform encephalopathy (BSE) (Ludwig & Bode, 2000). Antibodies to 
BDV have also been found in healthy dairy cattle in Japan (Hagiwara et al. 1996). Hagiwara 
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et al., (2008) also reported BDV in wild Japanese macaques that were captured due to 
agricultural damage.  
 
Feline BDV infection has not only been reported in Sweden, there have also been cases in 
Austria, Germany, Japan and Australia (Nowotny & Weissenbock, 1995; Huebner et al., 
2001; Nakamura et al., 1999; Kamhieh et al., 2006). Reports of BDV-antibodies in Japan by 
serology studies in house cats, with or without neurological signs was obtained by Nakamura 
et al., (1999). 
 
BDV infection has also been reported in humans with psychiatric disorders where antibodies, 
antigen and viral RNA were detected (for example Bode et al., 2001 & Nakamura et al., 
2000) However, these results have later been disputed (Dürrwald et al., 2007).  
 
Findings of BDV in different species and regions of the world indicate that BDV may be 
more widespread in a sub-clinical form, with probably long incubation periods. Furthermore, 
BDV may not necessarily be restricted to historically endemic areas as in eastern Germany 
(Ludwig & Bode, 2000). 
 
Genetic variation 
Several BDV strains have been sequenced from different animals as for example horses and 
sheep. Comparison of different BDV sequences revealed that most of the strains are closely 
related and that the nucleotide sequences do not differ more than 5 % (Kolodziejek et al., 
2005). European BDV sequences have non-random distribution of base exchange, indicating 
that the strains probably originate from a stable progenitor. However, some of the strains from 
horses, sheep and cat in Japan, Iran and United States are almost identical to the laboratory 
strain, V. Therefore there have been discussions of accidental contamination (Staeheli et al., 
2000).  
  
BDV infection in Sweden 
In Sweden, reports of BDV infection in horses, lynx and cats have been reported (Berg et al., 
1999; Degiorgis et al., 2000; Lundgren et al., 1997). A study of clinically healthy racing 
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horses and racing horses with diffuse neurological signs, showed higher BDV seroprevalence 
in the group with neurological signs and BDV RNA in blood samples was also found. These 
results indicate an association with BDV infection and atypical disease pattern as diffuse 
neurological signs in horses. This study included only 23 horses showing neurological signs, 
therefore further studies are needed to get a clearer knowledge about the epidemiology of 
BDV in horses in Sweden (Berg et al., 1999).  
 
In 1999, a free-ranging lynx was shot outside Gävle because of abnormal behaviour. 
Histopathological examination showed that the lynx suffered from non-suppurative 
meningoencephalitis, noticeable similar to SD, associated with BDV infection in cats 
(Degiorgis et al., 2000). The presence of BDV infection in the brain was confirmed by reverse 
transcriptase polymerase chain reaction (RT-PCR) analysis, immunohistochemistry and in 
situ hybridization. This is the only known case of BDV in lynx.  
 
The presence of BDV in Swedish cats has been confirmed by Lundgren et al. (1995), 
Wensman et al. (2007) and others. Most feline BD cases are reported around 
“Mälardalsregionen”, in the middle of Sweden. However, there have also been sporadic 
findings of BDV outside this region. Since the disease probably is wide-spread a deeper 
knowledge of molecular epidemiology of BDV is needed. 
 
Reservoirs unknown 
Based on the geographical localisation, seasonal pattern and animal species infected there is a 
hypothesis of a natural reservoir of BDV (Dürrwald et al., 2006). Furthermore, wild birds are 
known as a natural reservoir of viruses and therefore Berg et al. (2001) performed studies on 
faecal samples from wild birds in Sweden. The study showed that jackdaws and mallards 
could be infected carriers of BDV and thereby a reservoir of BDV. Recently, viral RNA was 
found in a bicoloured white-toothed shrew in endemic BD area in Switzerland (Hilbe et al., 





In cat, non-suppurative meningoencephalomyelitis of unknown etiology was first reported by 
Kronevi et al. (1974) where thirty cats with neurological disorders were examined. Changed 
behaviour as anxiety, more affection to the owner and muscular weakness in the hind-legs 
causing ataxia was observed. Within one to four weeks most of the cats died due to severe 
neurological signs. Lymphocytes and histiocytes, involved in the immune system were found 
in the spinal cord, meninges and brain. It has been confirmed that SD is not caused by other 
virus infections such as feline infectious peritonitis virus, feline leukaemia virus or feline 
immunodeficiency virus (Lundgren, 1992).   
  
Since the disease still had an unknown etiology the research continued and Lundgren & 
Ludwig (1993) established that the cause probably was BDV. It was confirmed by antibodies 
in Swedish cats with SD. The results showed an antibody prevalence of 44 % in affected cats. 
However, further studies as for example virus isolation was needed to confirm those results 
since BDV at that time only had been verified in sheep and horses. Lundgren et al. (1995) 
described presence of viral antigen and RNA using RT-PCR, immunohistochemistry and 
antigen-ELISA. The results showed BDV-specific antigen and RNA in feline CNS samples. 
Furthermore, a feline variant of BDV was isolated. However, further studies have to confirm 
the presence of BDV since the amount of BDV antigen and RNA in horses was higher 
compared to cats.  
 
An experimental infection in 1997, Lundgren et al. (1997) provided strong evidence that 
feline SD is associated with BDV. This was obtained by inoculating cats intracerebrally with 
feline BDV or BDV laboratory reference strain V from rabbit. The results showed that three 
out of eight cats developed neurological signs similar to SD as well as non-suppurative 
meningoencephalomyelitis. This is a strong indication that BDV is the etiological agent of 
SD.  
 
Clinical and histopathological signs 
SD has several clinical signs including changed behaviour like anxiety, depressive symptoms, 
increased mewing and more affection to the owner. Muscular weakness in the hind-legs 
causing ataxia, lumbosacral pain, inability to withdraw claws and a staring gaze is also 
observed (Kronevi et al., 1974; Lundgren 1992). Within one to four weeks the disease 
progress from sub-acute to chronic stage where most of the cats die due to severe signs 
described above. Since clinical signs alone could not be used for diagnosis of the disease 
further analysis is needed (Kamhieh & Flower, 2006). 
 
Histopathological findings in cats infected with BDV shows a non-purulent 
meningoencephalomyelit, mainly in the grey matter of the brain (mesencephalon), basal 
ganglia and hippocampus. Furthermore, BDV could also be found in cortex, see Figure 2 




Figure 2. Histopathology of brain tissue from a cat with SD (O.55/08). A characteristic perivascular 





The aim of this project was to get clearer knowledge about the spread of BDV and genetic 
diversity by comparing sequences from BDV affected cats and horses from different areas in 
Sweden. The approach was first to test different primer combinations to amplify overlapping 
parts of the BDV genome using classical PCR. The same approach was used for samples from 
cats with SD that previously have been positive for BDV. In order to get a broader picture of 
the possible etiological cause/s of SD, molecular screening of viruses using random 
amplification and sequencing were also performed (Allander et al., 2005). 
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Materials and methods 
Infected cells 
RNA from BDV infected C6 cells (C6BDV from strain He/80) were used for the optimisation 
of the different primers.  
 
Animals and tissue 
In total, seven of eight Swedish cats, clinically diagnosed with SD and non-suppurative 
meningoencephalomyelitis, were studied; O.69/93, O.423/92, O.388/96, O.65/07, O.55/08 
and O.65/08. The sample ID translates: identification number/year collected. Furthermore one 
cat (O.67/07) that showed no signs of infection in the CNS was also included since it had the 
same owner as O.65/07.  
 
Four of the cats; O.69/93, O.423/92, O.407/94 and O.388/96 had previously been positive at 
least once in nested PCR and real-time RT-PCR assays. Four cats; O.65/07, O.67/07, O.55/08 
and O.65/08 had only been histopathology examined. For detailed information of the cats, see 
Table 1. All samples were stored in -70°C freezer (Johansson et al., 2002; Wensman et al., 




Table 1. Clinically diagnosed SD cats from Sweden and earlier results from ELISA, real-time RT-PCR for 
BDVp23 and nested PCR for BDVp23 and BDVp40 (Johansson et al., 2002; Wensman et al., 2007; M Berg & J 





of brain.  
Year 
collected 
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Negative Positive Positive 
O.407/94: 
cortex 





BDV – pos 
by IFA, neg 
by ELISA 
Positive Positive Positive 
Detection of unknown DNA or RNA viruses and/or BDV 
O.65/07: cortex 2007 Non-supp 
meningoencephalitis 






2007 Negative section, no signs 
of infl in CNS 





















Molecular methods for detection and genetic characterization of 
BDV 
RNA extraction 
Total RNA was extracted from brain tissue samples; O.69/93, O.423/92, O.407/94 and 
O.388/96 according to RNeasy Lipid Tissue Mini Kit manual (Qiagen).  
 
Brain tissue samples of sizes about 0.5 cm3 were cut out and homogenized in 250 µl Qiazol 
(Qiagen) and thereafter further 500 µl Qiazol was added. The samples were incubated at room 
temperature for 5 minutes and then 150 µl of chloroform was added. The samples were 
shaken vigorously for 15 seconds and incubated for 2-3 minutes in room temperature and 
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centrifuged at 12 000 g for 15 min at 4°C to get three different phases in the following order, 
from upper phase to lower phase: colourless aqueous phase containing RNA; a white 
interphase containing DNA; red phase containing organic material. The aqueous phase 
volumes were estimated and then the same volume of 70% ethanol was added and the samples 
were mixed by vortexing. The samples were collected in an RNeasy Mini Spin Column 
(Qiagen) and centrifuged at ≥8000 g for 15 seconds at 25°C. To wash the columns, 700 µl 
buffer RW1 was added to the columns respectively, and centrifuged for 15 seconds at ≥8000 
g. The column were washed with additional 500 µl buffer RPE and centrifuged for 15 s at 
≥8000 g. Further 500 µl buffer RPE was added to each of the columns and the samples were 
centrifuged for 2 minutes at ≥8000 g to dry the RNeasy silica-gel membrane. The RNA was 
eluted by adding 30 µl RNase-free water and centrifuge for 1 minute at ≥8000 g. The elution 
procedure was carried out twice to get the total of 60 µl of RNA sample.   
 
The RNA concentration and purity were measured by NanoDrop ND-1000 spectrophotometer 
at 260/280 ratio. The ratios were over 1.8-1.9 suggesting that the samples were purified and 
clean. Therefore the procedure continued with cDNA synthesis. 
 
cDNA synthesis 
The RNA was converted to full-length cDNA using reverse transcriptase (RT) from 
SuperScriptTM III cDNA Synthesis System (Invitrogen). The mixture consisted of a total 
reaction of 40 µl where mixture I contained 2.5 mM random primer oliogonucleotides 
(pdN6), 0.5 mM dNTP mix (Fermentas) and 500 ng of total RNA. Mixture II contained 1× 
First Strand buffer (Invitrogen), 5 mM DTT (Invitrogen), 0.25 U ribonuclease (RNase) Out 
(Invitrogen) and 500 U of SuperScript III (Invitrogen). The reactions were incubated at 65°C 
for 5 minutes followed by 4°C for 5 minutes and during this time the samples were on ice for 
1 minute and thereafter mixture II was added. The reaction continued at 25°C for 5 minutes, 
50°C for 30 minutes, 55°C for 30 minutes and 70°C for 15 minutes. The cDNA synthesis was 




Different primer pairs were selected according to Kolodziejek et al. (2004). The primers were 
BDV1f, BDV218r, BDV587f, BDV652r, BDV778f, BDV796f, BDV1161r, BDV1327f, 
BDV1518r, BDV1695f, BDV1837r, and BDV2138r where the number indicate the nucleotide 
position in the BDV genome (strain V, accession number U04608). Furthermore, using 
primer design tools from Cybergene (Cybergene´s homepage, 2008) one more primer, 
BDV2383r was designed to overlap the wanted region. Other primer sequence pairs 
BDVp23A and BDVp23B, BDVp23C and BDVp23D, BDVp40A and BDVp40B, BDVp40C 
and BDVp40D, BDV gp18f and BDV gp18r have been used previously (Berg et al., 2001 and 
M Berg, unpublished data). See Appendix 1, Table A and Table B for primer sequences and 
primer pairs. All primers were ordered from DNA technology A/S. 
All primers were tested in C6BDV and thereafter used for classical PCR by using PhusionTM 
DNA polymerase (Finnzymes). Primer sequence pairs used for the first run in the nested PCR 
were BDVp23AB, BDVp40AB with BDVp23CD and BDVp40CD as inner pair for the 
second PCR, respectively.  
 
PCR analyses 
PCR amplification of cDNA was performed by PhusionTM DNA polymerase (Finnzymes). A 
master mix was prepared for a final 25 µl PCR reaction with the following components: 1× 
Phusion High-Fidelity (HF) Buffer, 0.2 mM dNTP mix (Fermentas), 4 U PhusionTM DNA 
polymerase (Finnzymes), 0.4 µM primers and 1 µl of cDNA or DEPC-H2O as negative 
control. Second nested PCR was performed with the same protocol with the exception of 
template that was 1 µl of PCR product from first nested PCR. Cycling conditions for first 
round and nested PCR was 98°C for 3 minutes, 35 cycles of amplification (30 seconds at 
98°C, 30 seconds at 60°C and 45 seconds at 72°C) followed by 72 °C for 4 minutes.  
 
BDV primer pairs that were used for O.388/96 and O.423/92 were following: BDV1f and 
BDV652r, BDV778f and BDVp23B, BDV1327f and BDVp23B, BDVp23C and BDV2383r. 
Nested PCR was performed for O.69/93, O.423/92, O.407/94 and O.388/96 by following 
primer pairs: BDVp40AB with nested primers BDVp40CD and BDVp23AB with nested 
primers BDVp23CD.  
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Comparison of the two enzymes, AmpliTaq® (Applied Biosystems) and PhusionTM 
(Finnzymes) was performed by using cDNA from O.388:96 and O.407:94. PCR amplification 
of cDNA was performed by PhusionTM DNA polymerase (Finnzymes) as described 
previously and PCR amplification by AmpliTaq® DNA polymerase (Applied Biosystems) 
was performed as following; a master mix was prepared for a final 25 µl PCR reaction with 
the following components: 1× GeneAmp PCR Buffer II (Applied Biosystems), 0.2 mM dNTP 
mixture (Fermentas), 2.5 mM MgCl2, 0.05 U/µl AmpliTaq® DNA polymerase (Applied 
Biosystems), 0.4 µM primers and 1 µl of cDNA sample or DEPC-H2O as negative control. 
Primer pairs that were used were: BDVp40AB with nested primers BDVp40CD and 
BDVp23AB with nested primers BDVp23CD. 
 
Cycling conditions for the classical PCR and the first round of nested PCR were 95°C for 2 
min, 35 cycles of amplification (30 seconds at 95°C, 30 seconds at 55°C and 90 seconds at 
72°C) followed by 72°C for 5 min and then 4°C. Cycling conditions for second run of the 
nested PCR were 95°C for 2 min, 40 cycles of amplification (30 seconds at 95°C, 30 seconds 
at 60°C and 30 seconds at 72°C) followed by 72°C for 5 min. 
 
In second nested PCR with AmpliTaq® DNA Polymerase (Applied Biosystems) the reaction 
was evaluated by changing the annealing temperature to following temperatures: 50.0°C, 
50.8°C, 51.7°C, 52.8°C, 54.1°C, 55.2°C 55.4°C, 55.8°C 56.7°C, 57.8°C 57.9°C, 58.8°C, 
59.1°C, 59.9°C, 60.4°C, 61.7°C, 62.9°C, 63.9°C and 64.9°C. The reaction was performed by 
using primer pairs: BDVp40CD and cDNA from O.407/94. 
 
Nested PCR with AmpliTaq® DNA polymerase (Applied Biosystems) were performed for 
four cats; O65/07, O.67/07, O.55/08 and O.65/08 that only had been histopathology 
examined. Used primer pairs were BDVp23AB, BDVp40AB with BDVp23CD and 
BDVp40CD as inner pair for the second PCR, respectively.  
 
Evaluation of cDNA synthesis 
Evaluation of cDNA samples for O.69/93, O.423/92, O.407/94 and O.388/96 were performed 
with real-time RT-PCR by using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), see  
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Appendix, Table A for sequences (Leutenegger et al., 1999). A master mix was prepared for a 
final 25 µl reaction with the following components: 1×Buffer II (Applied Biosystems), 4 mM 
MgCl2 (Applied Biosystems), 0.4 µM primer pairs GAPDH (BioSearch Technology), 0.5 µl 
Oligo nucleotide probe, 2.5 U AmpliTaq Gold® DNA Polymerase (Applied Biosystems) and 
1 µl of cDNA. As a positive control, cDNA from a feline mesenteric lymphnode was used and 
DEPC-H2O was used as negative control. Cycling conditions for real-time RT-PCR were 
95°C of 15 minutes followed by 45 cycles of amplification (95°C of 10 seconds and 60°C of 
45 seconds). The evaluation of cDNA was performed on a Rotorgene 3000, Corbett Research.  
 
Spiked RNA from C6BDV and infected cat 
Synthesis of cDNA was performed according to the protocol previously described. In cDNA 
synthesis reaction, RNA from the cats, O.388/96 and O.407/94 were spiked with RNA from 
C6BDV in different concentrations where C6BDV RNA was diluted in dilution buffer 
containing DEPC-H2O and 10 µg of sheared salmon sperm DNA (Ambion). A 10-fold 
dilution series from 1:100 to 1:1010 were made. Nested PCR with AmpliTaq® DNA 
polymerase (Applied Biosystems) was performed as previously described and primer 
sequence pairs were BDVp23AB, BDVp40AB with BDVp23D and BDVp40CD as inner pair 
respectively. 
 
Analysis of classical and nested PCR products 
PCR products from first round and nested PCR were analysed with gel electrophoresis. The 
products were purified using QIAquick PCR Purification Kit Protocol, (Qiagen) and products 
from gel electrophoresis were purified using QIAquick Gel Extraction Kit Protocol, (Qiagen). 
Thereafter 2 µl of purified PCR product was analysed on a gel to determine amount of 
product for cycle sequencing.  
 
Sequence analysis 
Cycle sequencing was performed by preparing a master mix for a final volume of 20 µl 
containing: 2 µl BigDye (Applied Biosystem), 3 µl sequencing buffer (Applied Biosystem), 2  
µM primer and 3-10 ng of PCR product. Cycling conditions for cycle sequencing was 25 
 15
cycles of amplification (95°C for 15 seconds, 50°C for 10 seconds and 60°C for 4 minutes). 
Cycle sequencing was followed by precipitation in room temperature by adding 2 µl of 3M 
natrium acetate (NaAc) and 40 µl of 99 % ethanol followed by vortex. The samples were kept 
in room temperature for 20 minutes and centrifuged at 13 000 rpm for 20 minutes. All ethanol 
was removed and 250 µl of 75 % ethanol was added. The samples were centrifuged at 13 000 
rpm for 20 minutes in room temperature. All ethanol was removed and the pellet was dried up 
for 10-15 minutes.  
 
Sequences were analysed with BioEdit sequence aligment editor and/or SeqMan from DNA-
Star Lasergene 7 (DNA-Star) and thereafter BLASTed at NCBIs homepage 
(www.ncbi.nlm.nih.gov/) by choosing nucleotide blast with highly similar sequences or more 
dissimilar sequences (2008-02-29; 2008-03-13; 2008-04-25; 2008-05-12) 
 
Detection of unknown viruses 
Molecular screening of DNA and RNA viruses using random amplification and sequencing 
were performed according to Allander et al. (2005) to detect possible unknown viruses. Four 
cats; O.65/07, O.67/07, O.55/08 and O.65/08, only histopathologically studied showing signs 
for SD, see Table 1.  
 
DNA and RNA extraction 
Brain tissue samples of sizes about 0.5 cm3 were cut out from each of the four cats and 
homogenized with a single-used pestle (Kontes Glass Company) and then homogenized with 
2 ml 1× DNase buffer (Roche). The homogenate was centrifuged with 4000 rpm. for 10 
minutes and thereafter the liquid phase was filtrated through a 0.45 µm syringe filter 
(Millipore). Ten µl of DNase I (10 U/µl) (Roche) and 4 µl of RNase (1µg/µl) were mixed 
with around 200-250 µl of homogenate.  
 
The DNA extraction was performed using QIAmp DNA Mini Kit according to the Blood and 
Body Fluid Spin Protocol (Qiagen). The RNA extraction was performed as described 
previously from the step where chloroform was added. The DNA and RNA concentrations 
and its purity were measured for each cat sample, by NanoDrop ND-1000 spectrophotometer. 
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DNA and RNA synthesis 
The extracted DNA and RNA samples were processed separately. Labelling and 2nd strand 
synthesis of the DNA samples were performed by preparing a master mix with a final volume 
of 15 µl containing: 10 μM primer FR26RV-N (DNA Technology), Neb 2 Buffer (New 
England Biolabs) and 10 mM of dNTP mixture (Fermentas), see Appendix, Table A for 
primer sequence. Template was 10 µl of pooled DNA from the four cats, using 2.5 µl from 
each cat. The sample was run at 94 °C for 2 minutes and incubated on ice for 2 minutes. 
Thereafter 0.5 µl of 3-5 exo-Klenow fragment of DNA polymerase (New England Biolabs) 
was added and sample run at 37 °C for 60 minutes, 94°C for 2 minutes and incubated on ice 
for 2 minutes. Thereafter additional 0.5 µl of 3-5 exo-Klenow fragment of DNA polymerase 
(New England Biolabs) was added and sample run on 37 °C for 60 minutes and 75 °C for 10 
min. Samples were stored at -20°C. 
 
cDNA synthesis and labelling of the RNA samples was performed by preparing a master mix 
with a final volume of 20 µl, where mixture I contained: 10 µM primer FR26RV-N (DNA 
Technology) and 1 of mM dNTPs mixture (Fermentas). Mixture II contained: 4 µl 5× First 
Strand Buffer (Invitrogen), 1 µl DTT (0.1 M) (Invitrogen), 1 µl Rnase out inhibitor 
(Invitrogen) and 1 µl of SuperScript II reverse transcriptase (Invitrogen). Ten µl of RNA from 
the four cats, 2.5 µl from each cat was used as template. The template was mixed with 
mixture I and run at 65°C for 5 minutes. The sample was kept on ice and mixture II was 
added and run at 25°C for 5 minutes, 50°C for 60 minutes and 70°C for 15 minutes. 0.5 µl of 
3-5 exo-Klenow fragment of DNA polymerase (New England Biolabs) was added and the 
sample was run at 37°C for 60 minutes and at 75°C for 10 min. Samples were stored at -20°C. 
Both syntheses of DNA and RNA samples reactions were performed on a thermal cycler, 
Minicycler (MJ Research).  
  
Pooled PCR 
Amplification was performed separated for DNA and RNA samples by preparing a master 
mix with a final volume of 50 µl PCR reaction with the following components: 1× GeneAmp 
PCR Buffer II (Applied Biosystems), 2.5 mM of MgCl2, 0.2 mM of dNTP mixture 
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(Fermentas), 0.8 µM pmol primer FR20RV (DNA Technology), 0.05 U/µl AmpliTaq Gold® 
DNA Polymerase (Applied Biosystems) and 5 µl of template, see Appendix, Table A for 
primer sequence. Cycling conditions for PCR was 95°C for 11 minutes and 40 cycles of 
amplification (95°C for 1 minute, 65°C for 1 minute and 72°C for 2 minutes). The amplified 
products were run on a 1.5 % agarose gel and thereafter purified by QIAquick PCR 
Purification Kit Protocol (Qiagen) and run on a gel again.  
 
Cloning 
Cloning was performed, separated for DNA and RNA samples, using pGEM®-T Easy Vector 
System I Kit (Promega) according to the manufacturer’s instruction by preparing a master mix 
of a total volume with 10 µl ligation product containing following components: 1× Rapid 
Ligation Buffer, 50 ng pGEM®-T Easy Vector, 0.5 μl T4 DNA Ligase and 4 μl of PCR 
product. The mixture was incubated at room temperature for one hour and thereafter 4 μl was 
used for ligation and the rest was incubated at 4°C for 16 hours. Ligation products were stored 
at -20°C.  
 
Four µl of ligation product was mixed carefully with 30 μl of competent cells (XL Blue), 
incubated on ice for 30 minutes followed by 42°C water bath for 45 seconds and one minute 
on ice. The cells were mixed with 0.5 ml of SOC Buffer (Invitrogen) and on shake for one 
hour at 37°C. Fifty µl of cells were growing on one LB/amp plate containing ampicillin 
(LB/amp). The rest of the ligation products were centrifuged for 3 minutes at 10.5 rpm, most 
of the supernatant discarded and the pellet dissolved in the remaining supernatant and put on a 
LB/Amp plate. The plated where placed in an incubator over night at 37°C. Single colonies 
on the LB/amp plates were picked and put in 2 ml of LB medium containing ampicillin and 
grown in a 37°C shaker for a maximum 15 hours. The samples were stored at 4°C.  
 
PCR screening 
Bacteria cells from cloning were used for PCR screening by preparing a master mix with a 
total volume of 25 μl containing following components: 1× GeneAmp PCR Buffer II 
(Applied Biosystems), 0.2 mM dNTP mixture (Fermentas), 2.5 mM MgCl2, 0.05 U/µl 
AmpliTaq® DNA polymerase (Applied Biosystems), 0.4 µM primer T6 and T7 (DNA 
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Technology) and 1 µl of grown bacteria. Cycling conditions for the PCR screening was 95°C 
for 12 minutes, 35 cycles of amplification (95°C for 30 seconds, 55°C for 30 seconds, 72°C 
for 90 seconds) followed by 72°C for 5 minutes. The PCR products were purified using Exo, 
SAP (Fermentas). Cycle sequencing and precipitating were performed as described previously 
with accept ion of a kit from Millipore. Sequences were edited in DNAStar Lasergene 7 
(DNAstar) and thereafter BLASTed on NCBIs homepage (2008-04-25; 2008-05-12). 
 
Real-time RT-PCR 
Real-time RT-PCR was performed according to Wensman et al. (2007) (BDVp23) and 
Schindler et al., (2007) (BDVp40) with minor modifications, by preparing a master mix for a 
final volume of 25 µl containing: 1× PCR Buffer (Applied Biosystems) 2.5 mM MgCl, 0.5 
mM dNTPs mixture (Fermentas), 0.08 mg/ml BSA, 0.7 µM primers, 0.3 µM probe for p23 or 
p40 gene and 0.1 U/µl of rTh-polymerase (Applied Biosystems). One µl of the first PCR 
product was used as template for primer pairs BDVp23AB, BDVp40AB with cDNA from 
O.407/94 and O.388/96. RNA and cDNA from O.407/94 and O.388/96 was also tested in the 
real-time RT-PCR.  
 
The following templates from O.65/07, O.67/07, O.55/08 and O.65/08 were also used: RNA 
from each of the four cats, pooled cDNA sample, pooled RT-PCR sample, purified pooled 
PCR sample and positive control in two different concentration of BDV infected C6 cells: 
C6BDV×10-5 and C6BDV×10-6. Cycle conditions were following: 5 minutes at 42°C and 20 
minutes at 60°C and followed by 55 cycles of amplification (5 seconds at 95°C and 30 
seconds at 50°C). The real-time RT-PCR of first nested PCR products, RNA and cDNA was 





Molecular methods for detection and genetic characterization of 
BDV 
Primer design 
To be able to amplify larger segment suitable for sequencing, different primer pairs were 
selected according to Kolodziejek et al. (2004), Berg et al. (2001) and M Berg (unpublished 
data). All primers were tested in C6BDV cells and thereafter used for classical PCR by using 
Phusion DNA polymerase (Finnzymes). All primer sequences and primer pairs that worked 
on C6BDV by using this enzyme are described in the Appendix, Table B. However, some of 
the primer combinations described by Kolodziejek et al. (2004) did not work and those are 
marked in italics in the Appendix, Table B. PCR products were purified and thereafter 
prepared for sequencing. Sequences were BLASTed at NCBIs homepage (2008-02-05) and 
revealed BDV sequences, strain He/80.  
 
PCR analysis  
First round and nested PCR with PhusionTM DNA polymerase were performed for samples 
O.69/93, O.423/92, O.407/94 and O.388/96 with different primer pairs, see Appendix, Table 
B, marked bold. Results from PCR with PhusionTM DNA polymerase showed no bands or 
bands at wrong sizes for BDVp23CD (391 bases) and BDVp40CD (429 bases). Therefore, a 
comparison of PCR with PhusionTM DNA polymerase and AmpliTaq® DNA polymerase were 
performed. Results from PCR with AmpliTaq® DNA polymerase showed band at correct sizes 
as well as wrong sizes. Several bands were seen in some reactions, see Figure 3A and 3B for a 





Figure 3A. PCR products with AmpliTaq® DNA 
polymerase were analyzed on a 1.5 % agarose gel. 
From left to right: M; DNA size marker (0.1 – 2 kb), 
1-4: Feline sample O.407/94 with primer pair 
BDVp23CD for 1 and 3 and BDVp40CD for 2 and 4, 
5-8: Feline sample O.388:96 with BDVp23CD for 5 
and 7 and BDVp40CD for 6 and 8, C: Negative 
control. 
Figure 3B. PCR products with PhusionTM DNA 
polymerase were analyzed on a 1.5 % agarose gel: 
From left to right: M; DNA size marker (0.1-2 kb), 
Feline sample O.407/94 with primer pair 
BDVp23CD for 1 and 3 and BDVp40CD for 2 and 4, 
5-8: Feline sample O.388:96 with BDVp23CD for 5 









Sequences from all PCR products were BLASTed at NCBIs homepage (2008-02-29) and all 
were found to be of feline origin with no presence of BDV. Evaluation of annealing 
temperature in second nested PCR with AmpliTaq® DNA polymerase was performed at 
temperatures between 50.0°C to 64.9°C and showed no significant difference between 
temperatures. Therefore the procedure continued with an evaluation of cDNA samples for 
O.69/93, O.423/92, O.407/94 and O.388/96 with real-time RT-PCR of feline GAPDH. All 
samples showed a positive result for GAPDH at 82 bases, except for the negative control, 
indicating that the cDNA quality is acceptable. 
 
Since the PCR analysis showed multiple unspecific bands, we wanted to evaluate the method. 
In order to do this, RNA from the cats, O.388/96 and O.407/94 was spiked with diluted 
C6BDV RNA, followed by nested PCR. Sequences from all bands were BLASTed at NCBIs 
homepage (2008-04-25) and yielded BDV for cat O.407/94 spiked with C6BDV cells  diluted 
1:106 (1A and 2A) for primer pair BDVp23CD and diluted 1:105 for primer pair BDVp40CD. 
The remaining PCR products yielded feline mRNA from the host and thereby no presence of 














Figure 4. Cat O.407/94 spiked with C6BDV cells in different concentrations. Second nested PCR with 
AmpliTaq® DNA polymerase were analyzed on a 1.5 % agarose gel. From left to right: L; DNA size marker (0.1 
– 2 kb), 1A-5A: Primer pair BDVp23CD with following concentration of C6BDV 1A: 1:105, 2A: 1:106, 3A: 
1:107, 4A: 1:108, 5A: 1:109, C: negative control. 1B-5B: Primer pair BDVp40CD with following concentration 
of C6BDV 1B: 1:105, 2B: 1:106, 3B: 1:107, 4B: 1:108, 5B: 1:109. 
 
Nested PCR for BDVp23 and BDVp40 with AmpliTaq® DNA polymerase was also 
performed for three cats, which had previously only been examined histopathologically; 
O65/07, O.55/08 and O.65/08. Furthermore, one more cat, O.67/07 that had the same owner 
as cat O65/07 was included. Sequences were BLASTed at NCBIs homepage (2008-04-25; 
2008-05-12) and showed feline mRNA from the host and thereby no presence of BDV. 
  
Detection of unknown viruses 
Since molecular detection of BDV failed, another approach that detects unknown viruses was 
used on only histopathologically examined cats, showing signs for SD. Three cats; O65/07, 
O.55/08 and O.65/08 showing SD was chosen. Furthermore, one more cat, O.67/07 that came 
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from the same owner as cat O65/07 was included, see Table 1. All samples were used for 
RNA and DNA extraction and the cDNA for RNA viruses and DNA for DNA viruses were 
pooled for all four cats. The DNA and the cDNA samples were used for random PCR 
amplification and followed by cloning of the purified PCR products. Finally the cloned PCR 
products were prepared for sequencing which resulted in a total of 113 RNA sequences and 
41 DNA sequences. Sequences were edited in DNAStar Lasergene 7, showing 15 contigs (74 
sequences between 240-560 bases) for RNA and 4 contigs (8 sequences between 200-430 
bases) for DNA. The consensus sequences from all contigs were BLASTed at NCBIs 
homepage (2008-04-25; 2008-05-12) by using BLASTn. All sequences were defined as host 




Real-time RT-PCR is considered to be a more sensitive method and therefore real-time RT-
PCR for BDVp23 and BDVp40 were performed, using cDNA, first PCR product and RNA as 
template from O.69/93, O.423/92, O.407/94 and O.388/96. Real-time RT-PCR did not reveal 
the presence of BDV.  
 
Since both nested PCR and detection of unknown viruses showed no presence BDV, real-time 
RT-PCR was performed to confirm that one or several of the cats had BDV infection. Real-
time RT-PCR with BDVp23 was performed for the following templates from O.65/07, 
O.67/07, O.55/08 and O.65/08. As templates, extracted RNA from each of the four cats, 
pooled cDNA sample, pooled PCR sample, purified pooled PCR sample and positive control 
in two different concentrations of C6BDV were used. The real-time RT-PCR yielded positive 
results for the purified pooled PCR product in the curve between the two positive controls 
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Figure 5. Real-time RT-PCR results. Starting from the uppermost curve: C6BDV 1:105, purified pooled PCR 
samples and C6BDV 1:106. The remaining curves correspond to extracted RNA from O.65/07, O.67/07, O.55/08 
and O.65/08 and pooled RT-PCR sample. 
 
The positive real-time PCR products were confirmed by cloning PCR products and thereafter 
sequencing. Sequences were BLASTed at NCBIs homepage and showed BDV for all 





The aim of this project was to gain clearer understanding about the spread and the genetic 
diversity of BDV by comparing sequences from BDV infected cats and horses from different 
areas in Sweden. BDV is associated with SD, a feline neurological disorder. However, cats 
showing signs of SD are not always confirmed to have BDV infection. In general, these types 
of chronic infections are extremely difficult to confirm. Therefore, another approach that 
detects unknown viruses and/or BDV using a broader molecular screening of viruses was 
evaluated. 
 
Different primer pair was tested in C6BDV using first and nested PCR with PhusionTM DNA 
polymerase. However, some of the primer pairs from Kolodziejek et al. (2004) failed (see 
Appendix, Table B). There is no obvious explanation why these primer combinations failed. 
Kolodziejek et al. did use another polymerase enzyme but one would not expect that to have 
such a dramatic affect on the success of the PCR amplification. Another explanation, though 
unlikely, could be that the synthesis of the primers has failed. All PCR products were 
sequenced and all of them showed as expected BDV, strain He/80.  
 
The project continued with first and nested PCR for four samples, previously positive in 
nested PCR and real-time RT-PCR (see Table 1). However, this study showed either none or 
several bands within one PCR product and/or bands at wrong sizes. Since the cats had been 
previously positive, a comparison of the enzymes PhusionTM DNA polymerase and 
AmpliTaq® DNA polymerase, with higher precision, was performed. The comparison 
indicated that AmpliTaq® DNA polymerase was more reliable (Figure 3A and 3B). However, 
sequencing of PCR products at correct sizes showed only host RNA and thereby no presence 
of BDV. Therefore an evaluation of annealing temperature in second nested PCR was 
performed. The temperature showed no significant difference in bands, indicating that the 
annealing temperature is correct. Consequently an evaluation of the cDNA product was 
performed where all products were positive, indicating that the cDNA quality is acceptable. 
Pooled cDNA samples used for detection of unknown viruses approach (see Table 1) were 
also used in nested PCR, with PCR products at correct sizes. Again, sequencing showed only 
feline protein.  
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Because BDV occurs at low levels in brain tissue, a more sensitive method like real-time RT-
PCR also was performed. However, real-time RT-PCR was negative for the old samples used 
in molecular epidemiology (Table 1).  
 
Since nested PCR failed, no phylogenetic analysis on BDV was able to be performed as 
initially planned. The lack of results from first and nested PCR as well as real-time RT-PCR 
could be explained as being due to BDV infected cats having a small amount of virus in brain 
compared to horses. However, the cats that had previously shown positive results for nested 
PCR (M. Berg, unpublished data) as well as real-time RT-PCR (Wensman et al., 2007) should 
yield positive results. Therefore, another explanation could be that the RNA from the virus 
had degraded through thawing and freezing since the brain samples had been used several 
times. Another reason could be that the RNA extraction method is not optimal. There is 
always a risk that the RNA disappears through the extraction steps and when the sample 
contain small amount of RNA this step is crucial. Another reason might be that the particular 
piece of brain tissue chosen did not contain BDV.  
 
Because there were no BDV sequences in the molecular epidemiology approach a broader 
approach was used, according to Allander et al. (2005), to detect unknown DNA and/or RNA 
viruses, and maybe BDV. The samples were pooled and contained brain tissue from four new 
cats only examined by histopathology, where three showed signs for SD (Table 1). The 
pooled samples, one for detection of RNA viruses and one for DNA viruses were used for 
PCR and followed by cloning. Sequencing of cloned PCR products resulted in a total of 113 
RNA sequences and 41 DNA sequences with 15 and 4 contigs, respectively. However, all 
sequences were defined as feline host DNA for DNA samples and feline host RNA for RNA 
samples.  
 
Since the approach to detect unknown DNA or/and RNA viruses involves sequencing several 
samples to get even just a single virus, more sequencing of clones has to be performed to 
confirm the presence of viruses. This requires more laboratory work, and another issue could 
be cost of multiple sequencing. It is also difficult to get rid of host DNA and RNA. In 
particular, host ribosomal mRNA is an issue for detection of RNA viruses. Therefore an 
optimization of this method is needed. There are also some bioinformatics problems as how to 
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continue with unknown sequences not found in the available databases. The databases could 
also contain incorrect annotations.  
 
Real-time RT-PCR was negative for the old samples used in molecular epidemiology 
although positive for the pooled sample used in detection of unknown viruses (see Table 1 
and Figure 5). The positive real-time RT-PCR shows that BDV is a contributory factor for SD 
in cats. There is probably a need of more sensitive methods to perform molecular genetics 
studies on BDV infected cats. One method to improve the effectiveness of PCR by BDV may 
be to isolate virus from cat brain in cell cultures to increase the amount of virus, thereby there 
yielding more material to work with. 
 
Conclusion 
This project has identified some of the problems of studying RNA viruses in small amounts in 
brain tissue. There is always a risk that the RNA is lost during the RNA extraction process 
and, when the sample contains very low RNA levels to begin with, the extraction step is 
particularly crucial. Furthermore, RNA can degrade when the sample is thawed and frozen 
several times. Another factor may be that the causative virus, due to intense immune reaction, 
has disappeared. Since molecular epidemiology of Borna disease in Sweden remains largely 
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Appendix 
Table A. Primer sequences that were used in classical and nested PCR (Kolodziejek et al., 2005; J. Wensman & 
M. Berg, unpublished data), real-time RT-PCR for BDVp23 (Wensman et al., 2007), evaluation of cDNA with 
real-time RT-PCR for GAPDH (Leutenegger et al., 1999) and PCR screening with FR26RV-N and FR20R in 
detection of unknown viruses (Allander et al., 2005).  
Classical and nested PCR 
Forward (position) Bases 
BDV1f 5´-GTTGCGTTAACAACMAACCA-3´ 
BDV218f 5´-GAACGCAGTGGCATTGTTAG-3´ 




BDVp23A (1391) 5´-TGACCCAACCAGTAGACCCA-3´ 
BDV1695f 5´-GATCGCTCCATGAAGACAAT-3´ 
BDVgp18f (1893) 5´-GAACGCAGTGGCATTGTTAG-3´ 
BDVp23C (1447) 5´-TCAGACCCAGACCAGCGAA-3´ 
BDVp40C (452) 5´-TCTCCTCTATCTTCAGCCATTGTTGC-3´ 





BDVp40B (1006) 5´-GGAGTAAGAAGGAAAACCCCACAATGG-3´ 
BDV1518r 5´-AAGTTAGTGACGGAGCTGG-3´ 
BDV1837r 5´-GCATTTATCCCCAGCTCCCA-3´ 
BDVp23B (1869) 5´-GACAACGGATGAATGGGACA-3´ 
BDV2138r 5´-ACTTCCAGATTGACGACTTC-3´ 
BDV2383r 5´-GAGATAAGGCGACTTTGCCA-3´ 
BDVgp18r (2321) 5´-CGCGTCGACCTAAGGCCCTGAAGATCG3´  
BDVp23D (1838) 5´-CGCGCATTTATCCCCAGCT-3´ 




real-time RT-PCR  
BDVp23f 5´-GAACCCCTCCATGATCTCAGAY-3´ 
BDVp23r 5´-CTCYGTCACTAGCTTCTTGATRAG-3´ 
BDVp23 probe 5´-CAGCGAACCGGAAGGGAGCAGCTATC-3´ 





Table B. Primer sequence pairs that worked in classical and nested PCR with AmpliTaq® DNA polymerase for 
C6BDV, He/80. Those combinations that failed are marked as italic and those that the project continued with are 
marked as bold (Kolodziejek et al., 2005; J. Wensman & M. Berg, unpublished data).  
Forward (position) Reverse (position) Length 
BDV1f BDV652r 652 
BDV1f BDV1161r 1161 
BDV1f BDVp23B (1869) 1868 
BDV218f BDV796r 578 
BDV218f BDV1161r 943 
BDVp40A (278) BDVp40B (1006) 728 
BDV587f BDV1161r 574 
BDV587f BDV1518r 931 
BDV587f BDV2138r 1551 
BDV778f BDV1161r 383 
BDV778f BDV1518r 740 
BDV778f BDVp23B (1869) 1091 
BDV1327f BDV1837r 510 
BDV1327f BDVp23B (1869) 542 
BDVp23A (1391) BDVp23B (1869) 478 
BDVp23A (1391) BDV2138r 747 
BDV1327f BDV2383r 1056 
BDVp23C (1447) BDV2383r 936 
BDV1695r BDVp23B (1869) 164 
BDV1695r BDV2138r 443 
BDVgp18f (1893) BDV2383r 490 
BDVgp18f (1893) BDVgp18r (2321) 428 
BDVp23C (1447) BDVp23D (1838) 391 
BDVp40C (452) BDVp40D (881) 429 
 
 
  
 
 
